Back to NAI500

Company Profile

GH Therapeutics Co., Ltd. is a biotechnology company engaged in the research and development of innovative drugs. The company was established on July 4, 2022, with its registered address at 1401, Block B, No. 16 Lanjing Middle Road, Pingshan District, Shenzhen City, located in the Medical Research and Transformation Center of Shenzhen Bay Laboratory. The English name of the company is “GH Therapeutics Co., Ltd.”. The company currently has 5 products under research for different targets, which are in the stages of early research and development, molecular optimization and preclinical development, and the indications include antifungal infection and anti-tumor.

Corporate Speaker

Dr. Wenlian Xu

Co-Founder & CEO

Wenlian Xu, currently the co-founder and CEO of GH Therapeutics Co., Ltd., holds a bachelor’s degree from Anhui Normal University and a Ph. D. degree from Nanjing Agricultural University. Before founding GH Therapeutics, he has ever been an associate professor at Tsinghua University, a research Scientist at Johns Hopkins University, a vice president of Joinn Laboratory USA Co. Ltd., and the deputy general manager of 3D Medicines (Beijing) Co., Ltd. He has published more than 30 professional academic papers and led the team to have complete the clinical development of phase I and the first registered indication, as well as its marketing application of the world’s first, subcutaneous injection, anti-PD-L single-domain antibody KN035.